Multidisciplinary Approach to Post-Liver Transplant Obesity: Challenges and Therapeutic Perspectives
Open Access
- 9 November 2026
- journal article
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- p. e4826
Abstract
The global epidemiological transition of chronic liver diseases has consolidated Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its inflammatory form, Metabolic Dysfunction-Associated Steatohepatitis (MASH), as emerging and predominant indications for liver transplantation in the current era1. However, the resolution of end-stage liver failure by surgery exposes the recipient to a new and complex challenge: the "second metabolic hit," induced by continuous immunosuppressive therapy (especially calcineurin inhibitors and corticosteroids). This pharmacological intervention, associated with appetite recovery and improvement in prior nutritional status, triggers accelerated weight gain, development of new-onset diabetes after transplantation (NODAT), dyslipidemia, and recurrent or de novo steatosis in the allograftThis publication has 4 references indexed in Scilit:
- Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?Biomedicines, 2023
- Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysisSurgery for Obesity and Related Diseases, 2019
- New-onset obesity after liver transplantation-outcomes and risk factors: the Swiss Transplant Cohort StudyTransplant International, 2018
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015